Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.

As seen previously, protection waned if T-705 therapy was initiated on day 6; however, in this experiment, the reduced efficacy observed (50% survival) was highly significant compared to the placebo control (P<0.001).

also in 132,142 other papers